Neurovascular unit senescence as a driver of blood-brain barrier dysfunction in Alzheimer's disease: mechanisms, consequences, and therapeutic implications.
Cellular aging in brain blood vessels drives Alzheimer's damage earlier than amyloid, suggesting aging-targeted drugs might modify disease without waiting for amyloid clearance.
This Ageing Research Reviews article synthesizes evidence that cellular senescence across all components of the neurovascular unit is a major mechanistic driver of blood-brain barrier breakdown in Alzheimer's disease, preceding and potentially amplifying amyloid and tau pathology. Senolytics and senomorphics targeting NVU senescence are proposed as upstream therapeutic interventions that could modify the disease course without depending on amyloid clearance.
What the study was
- Study design
- narrative_review
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Ageing Res Rev
Why it surfaced
Ageing Research Reviews is a top-quartile aging journal; NVU senescence in AD connects the aging and neurodegeneration watchlist topics; senolytics as a therapeutic strategy is an emerging clinical priority with implications across multiple neurodegenerative diseases.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.